

Reference Sheet

1. D'Mello, R., and A.H. Dickenson, "Spinal Cord Mechanisms of Pain," *British Journal of Anaesthesia* 101, no. 1 (2008): 8-16. <https://pubmed.ncbi.nlm.nih.gov/18417503/>
2. Harte, Steven E., "The Neurobiology of Central Sensitization," *Journal of Applied Biobehavioral Research*, Volume: 23, Issue: 2 (2018): n. page
<https://onlinelibrary.wiley.com/doi/full/10.1111/jabr.12137>
3. Russo, et al., "Brain Modularity Controls the Critical Behavior Spontaneous Activity," *Scientific Reports* 4 (2014): 4312 .<https://www.nature.com/articles/srep04312>
4. Woolf, C.J., "Pain: Moving from Symptom Control toward Mechanism-Specific Pharmacologic Management," *Annals of Internal Medicine* 140 (2004): 441-451.
<https://www.acpjournals.org/doi/10.7326/0003-4819-140-8-200404200-00010>
5. Giordano, J., and M.E. Schatman., "An Ethical Analysis of Crisis in Chronic Pain Care: Facts, Issues, and Problems in Pain Medicine; Part 1," *Pain Physician* 11 (2008): 483-490.
<https://pubmed.ncbi.nlm.nih.gov/18690277/>
6. Treede, R.-D., et al., "Chronic Pain as a Symptom or a Disease: The IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11)," *Pain* 160, no. 1 (2019): 19–27.
https://journals.lww.com/pain/abstract/2019/01000/chronic_pain_as_a_symptom_or_a_disease_the_iasp.3.aspx
7. Aydede, M., and A. Shriver, "Recently Introduced Definition of 'Nociplastic Pain Needs Better Formulation,'" *Pain* 159, no. 6 (2018): 1176-1177.
https://journals.lww.com/pain/citation/2018/06000/recently_introduced_definition_of_nociplastic.22.aspx
8. Nahin, R.L., et al., "Estimated Rates of Incident and Persistent Chronic Pain Among US Adults, 2019-2020," *JAMA Network Open* 6, no. 5 (2023): e2313563.
doi:10.1001/jamanetworkopen.2023.13563
<https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2804995>
9. Linton, S.J., and W.S. Shaw, "Impact of Psychological Factors in the Experience of Pain," *Physical Therapy* 91, no. 5 (2011): 700-711. <https://academic.oup.com/ptj/article/91/5/700/2735743>.
10. Levy, N., J. Sturgess, and P. Mills, "'Pain as the Fifth Vital Sign' and Dependence on the 'Numerical Pain Scale' Is Being Abandoned in the US: Why?" *British Journal of Anaesthesia* 120, no. 3 (2018): 435-438. [https://www.bjanaesthesia.org/article/S0007-0912\(17\)54182-3/fulltext](https://www.bjanaesthesia.org/article/S0007-0912(17)54182-3/fulltext)
11. Burns, J.W., et al., "Cognitive Therapy, Mindfulness-Based Stress Reduction, and Behavior Therapy for the Treatment of Chronic Pain: Randomized Controlled Trial," *Pain*, 2022; 163 (2):

376–389.

https://journals.lww.com/pain/abstract/2022/02000/cognitive_therapy_mindfulness_based_stress.13.aspx

12. Aronson, M.D., "Nonsteroidal Anti-Inflammatory Drugs, Traditional Opioids, and Tramadol: Contrasting Therapies for the Treatment of Chronic Pain." *Clin Ther* 1997;19:420-432. <https://pubmed.ncbi.nlm.nih.gov/9220207/>
13. Bovill, J.G., "Mechanisms of Actions of Opioids and Non-Steroidal Anti-Inflammatory Drugs." *European Journal of Anaesthesiology* Suppl 1997;15:9-15. https://journals.lww.com/ejanaesthesiology/abstract/1997/05001/mechanisms_of_actions_of_opioids_and_non_steroidal.3.aspx
14. Ackerman, W.E., "Paroxysmal Opioid-Induced Pain and Hyperalgesia." *J Ky Med Assoc* 2006; 104:419-23. <https://pubmed.ncbi.nlm.nih.gov/17100120/>
15. Marudhai, S., et al., "Long-term Opioids Linked to Hypogonadism and the Role of Testosterone Supplementation Therapy," *Cureus* 12, no. 10 (2020): e10813. <https://www.cureus.com/articles/41689-long-term-opioids-linked-to-hypogonadism-and-the-role-of-testosterone-supplementation-therapy#!/>
16. Godwin, B., et al., "Identification and Management of Opioid-induced Neurotoxicity in Older Adults." *Canadian Family Physician* 68, no. 4 (2022): 269-270. <https://www.cfp.ca/content/68/4/269>
17. Franchi, et al., "Do All Opioid Drugs Share the Same Immunomodulatory Properties? A Review from Animal and Human Studies," *Frontiers in Immunology* (2019), <https://doi.org/10.3389/fimmu.2019.02914>
18. Eisenstein, T.K., "The Role of Opioid Receptors in Immune System Function," *Frontiers in Immunology* (2019), <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934131/>
19. Roy, et al., "Opioid Drug Abuse and Modulation of Immune Function: Consequences in the Susceptibility to Opportunistic Infections," *Journal of Neuroimmune Pharmacology* 6, no. 4 (2011): 442–465. <https://europepmc.org/article/med/21789507>
20. Padilla, et al., "HIV Stigma and Health Care Discrimination Experienced by Hispanic or Latino Persons with HIV — United States, 2018–2020" *MMWR Morbidity and Mortality Weekly Report* 71, no. 41 (2022): 1308-1310. <https://www.cdc.gov/mmwr/volumes/71/wr/pdfs/mm7141-H.pdf>
21. O’Kelly, B., et al., "Safety and Efficacy of Low Dose Naltrexone in a Long Covid Cohort; An Interventional Pre-post Study." *Brain, Behavior, and Immunity – Health* 24 (2022): 100485. <https://pubmed.ncbi.nlm.nih.gov/35814187/>

22. Weiner, S.G., "Factors Associated with Opioid Overdose After an Initial Opioid Prescription," *JAMA Network Open*. 2022;5(1):e2145691. doi:10.1001/jamanetworkopen.2021.45691. <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788462>
23. Hallvik, et al., "Patient outcomes after opioid dose reduction among patients with chronic opioid therapy," *Pain*, 2022; 163 (1): 83-90. <https://pubmed.ncbi.nlm.nih.gov/33863865/>
24. Roy, et al., "Opioid Drug Abuse and Modulation of Immune Function: Consequences in the Susceptibility to Opportunistic Infections," *J Neuroimmune Pharmacol.* 2011 Dec; 6(4): 442–465. <https://link.springer.com/article/10.1007/s11481-011-9292-5>
25. Serafini, R.A., et al., "The Mesolimbic Dopamine System in Chronic Pain and Associated Affective Comorbidities," *Biological Psychiatry*. 2020 Jan 1; 87(1): 64–73. doi: 10.1016/j.biopsych.2019.10.018. [https://www.biologicalpsychiatryjournal.com/article/S0006-3223\(19\)31816-5/abstract](https://www.biologicalpsychiatryjournal.com/article/S0006-3223(19)31816-5/abstract)
26. Reckziegel, D., et al., "Deconstructing Biomarkers for Chronic Pain: Context- and Hypothesis-Dependent Biomarker Types in Relation to Chronic Pain," *Pain*, 2019; 160, S37-S48. <https://pubmed.ncbi.nlm.nih.gov/31008848/>
27. Castellanos, et al., "Chronic Pain and Psychedelics: A Review and Proposed Mechanism of Action." *Regional Anesthesia and Pain Medicine*. 2020; 45 (7). <https://rapm.bmj.com/content/45/7/486>
28. De Andres, J., et al., "Intrathecal Drug Delivery: Advances and Applications in the Management of Chronic Pain Patient." *Frontiers in Pain Research*. 2022; 3:900566. doi: 10.3389/fpain.2022.900566. <https://www.frontiersin.org/articles/10.3389/fpain.2022.900566/full>
29. Olson, M.E., and K.D. Janda, "Vaccines to Combat the Opioid Crisis," *EMBO Reports*. (2017) 19:5-9. <https://doi.org/10.15252/embr.201745322>.
30. Haile, C.N., et al., "An Immunconjugate Vaccine Alters Distribution and Reduces the Antinociceptive, Behavioral and Physiological Effects of Fentanyl in Male and Female Rats," *Pharmaceutics*. 2022; 14(11): 2290. doi: 10.3390/pharmaceutics14112290. <https://www.mdpi.com/1999-4923/14/11/2290>
31. Diatchenko, L., et al., "Omics Approaches to Discover Pathophysiological Pathways Contributing to Human Pain," *Pain*, 2022, 163(S1):S69-S78. <https://pubmed.ncbi.nlm.nih.gov/35994593/>